

ASX Announcement11 November 2020

Antisense Therapeutics Limited raises A\$7.3 million in oversubscribed Placement

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY], (the Company) is pleased to announce it has received firm commitments under an institutional placement to raise A\$7.3 million via an issue of approximately 73.0 million new fully paid ordinary shares (New Shares), representing approximately 15.0% of ANP's existing issued capital, at an offer price of A\$0.10 per share (**Placement**). Following completion of the Placement, ANP will also conduct a share purchase plan targeting to raise A\$1 million (**SPP Offer**) at the same price.

ANP intends to use the proceeds from the Placement and SPP Offer (together, the **Capital Raising**) for:

- Manufacturing of the drug compound and clinical supplies for the upcoming planned Phase IIb European clinical trial of ATL1102 in DMD;
- Other preparatory work for the trial including interactions with EU regulatory consultants and authorities;
- Advancing plans with the US FDA for ATL1102 in DMD including interactions with US regulatory consultants and meeting(s) with the FDA;
- Advancing new indication initiatives for ATL1102 including potential animal pharmacology studies and associated costs for the filing of new possible IP; and
- General working capital.

Placement

The Placement was conducted at A\$0.10 per New Share, which represents a 13% discount to the last closing price of ANP shares on the ASX on 9 November 2020, being A\$0.115 per share and a 2.3% discount to the five-day VWAP (up to and including 9 November 2020).

The New Shares issued under the Placement will rank equally with existing ANP fully paid ordinary shares on issue. ANP will issue the New Shares without shareholder approval in accordance with its existing placement capacity under ASX Listing Rule 7.1.

The Joint Lead Managers to the Placement are Wilsons Corporate Finance Limited (ABN 65 057 547 323) ("**Wilsons**") and Morgans Corporate Limited ("**Morgans**") (ABN 32 010 539 607). XEC Partners Pty Ltd ("**XEC**") acted as Corporate Adviser to the Company.

Settlement of the New Shares issued under the Placement is expected to occur on Tuesday, 17 November 2020, with allotment of the New Shares issued under the Placement scheduled for Wednesday, 18 November 2020.

Share Purchase Plan

Following completion of the Placement, ANP will conduct an offer of New Shares under a share purchase plan targeting A\$1 million to existing shareholders of the Company:

- (a) who have a registered address in Australia or New Zealand as at 7.00pm on Tuesday, 10 November; and

- (b) who are not in the United States or acting for the account or benefit of a person in the United States.

The SPP Offer will provide each eligible shareholder with the opportunity to apply for up to A\$30,000 worth of New Shares at the issue price under the Placement (being A\$0.10).

The Company reserves the right to either increase or decrease the maximum or scale back applications in its absolute discretion. It is the Company's intention that any scale back arrangements will be made having regard to the pro rata shareholdings of Eligible Shareholders who apply for Shares under the Offer. However, the Company may in its absolute discretion determine to apply the scale back to the extent and in the manner it sees fit, which may include taking into account a number of factors such as the size shareholding at the SPP Record Date, the extent to which Shares have been sold or purchased since the SPP Record Date, the date on which an application was made and the total applications received from Eligible Shareholders.

The New Shares issued under the SPP Offer will rank equally with existing ANP fully paid ordinary shares on issue.

The SPP offer document (**SPP Booklet**) containing further details of the SPP Offer will be released on the ASX separately and is expected to be mailed to all eligible shareholders in Australia and New Zealand on or about Wednesday, 18 November 2020 being the date on which the SPP Offer will open.

ANP will seek quotation of the New Shares issued under the Placement and the SPP Offer on the ASX.

Equity Raising Indicative Timetable*

Event	Date (2020)
Record date for eligible shareholders to subscribe for New Shares via the SPP Offer	Tuesday, 10, November
Trading halt	Tuesday, 10, November
Placement bookbuild	Tuesday, 10, November
Announcement of results of Placement	Wednesday, 11, November
Settlement of Placement	Tuesday, 17, November
Allotment of New Shares issued under the Placement	Wednesday, 18, November
SPP Booklet despatched to shareholders	Wednesday, 18, November
SPP Offer opens	Wednesday, 18, November
SPP Offer closes	Thursday, 26, November
Allotment of New Shares issued under the SPP Offer	Wednesday, 2, December
Despatch of holding statements	Tuesday, 3, December

Normal trading of New Shares issued under SPP Offer

Friday, 4, December

** These dates are indicative only and are subject to change. ANP, reserves the right, subject to the Corporations Act 2001 (Cth) and the ASX Listing Rules, to amend this indicative timetable. In particular, ANP reserves the right to extend the Closing Date, accept late applications under the SPP Offer (either generally or in particular cases), and to withdraw or vary the SPP Offer without prior notice. Any extension of the Closing Date will have a consequential effect on the date for the allotment and issue of New Shares.*

Additional Information

Further details on ANP's business, the Placement and the SPP Offer are set out in the investor presentation provided to the ASX today and are also available to eligible persons not in the United States at the Company's website at www.antisense.com.au. The investor presentation contains important information including key risks relating to ANP and an investment in ANP shares. Any person considering an investment in ANP shares should read the investor presentation and seek their own independent advice before making any decision in this regard.

Mark Diamond, ANP's Managing Director and CEO said: "We thank Morgans and Wilsons for the strong support from their respective networks in the Placement, which was significantly oversubscribed, with a number of new institutional investors joining the Company's register. This Capital Raising significantly strengthens the balance sheet and we thank our supportive shareholders and welcome new investors as we look to advance ATL1102 into late stage clinical development for DMD".

This announcement has been authorised for release by the Board.

For more information please contact:

Antisense Therapeutics

Mark Diamond
 Managing Director
 +61 (0)3 9827 8999
www.antisense.com.au

Investment Enquiries

Gennadi Koutchin
 XEC Partners
gkoutchin@xecpartners.com.au
 1300 932 037

About Antisense Therapeutics Limited (ASX:ANP | US OTC:ATHJY) is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.

About ATL1102 ATL1102 is an antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4). Antisense inhibition of VLA-4 expression has demonstrated activity in a number of animal models of inflammatory disease including asthma and MS with the MS animal data having been published in a peer reviewed scientific journal. ATL1102 was shown to be highly effective in reducing MS lesions in a Phase IIa clinical trial in patients with RR-MS. The ATL1102 Phase IIa clinical data has been published in the medical Journal *Neurology* (Limmroth, V. et al Neurology, 2014; 83(20): 1780-1788).

About ATL1102 DMD Trial The Phase II clinical trial of ATL1102 in patients with Duchenne Muscular Dystrophy was an open label six-month dosing trial of ATL1102 administered SC at 25mg per week in nine non-ambulant patients with DMD aged between 10 and 18 years. The trial was conducted at the neuromuscular centre of the Royal Children's Hospital (RCH) in Melbourne, Australia. The primary endpoints of the trial related to the safety

and tolerability of ATL1102. The efficacy of ATL1102 was also assessed in terms of its effects on disease processes and progression (e.g. the upper limb strength and function of the boys). Given the exploratory nature of this first trial in boys with DMD, it was not powered to see a statistical difference on these disease progression endpoints, which would be expected in future longer-term clinical studies in a larger number of patients. However, highly encouraging positive trends across multiple parameters have been reported in this Phase II clinical trial. Further details on the trial are available [here](#) on the Australia and New Zealand Clinical Trials Registry.

About DMD Duchenne Muscular Dystrophy (DMD) is an X-linked disease that affects 1 in 3600 to 6000 live male births (Bushby *et al*, 2010). DMD occurs as a result of mutations in the dystrophin gene which causes a substantial reduction in or absence of the dystrophin protein. Children with DMD have dystrophin deficient muscles and are susceptible to contraction induced injury to muscle that triggers the immune system which exacerbates muscle damage as summarized in a publication co-authored by the Director of the FDA CDER (Rosenberg *et al*, 2015). Ongoing deterioration in muscle strength affects lower limbs leading to impaired mobility, and also affects upper limbs, leading to further loss of function and self-care ability. The need for wheelchair use can occur in early teenage years for patients on corticosteroids with a mean age of 13, with respiratory, cardiac, cognitive dysfunction also emerging. Patients with a greater number of immune T cells expressing high levels of CD49d have more severe and progressive disease and are non-ambulant by the age of 10 despite being on corticosteroid treatment (Pinto Mariz *et al*, 2015). With no intervention, the mean age of life is approximately 19 years. The management of the inflammation associated with DMD is currently addressed via the use of corticosteroids, however they are acknowledged as providing insufficient efficacy and are associated with significant side effects. As a consequence, there is an acknowledged high need for new therapeutic approaches for the treatment of inflammation associated with DMD.

Rosenberg AS, Puig M, Nagaraju K, *et al*. Immune-mediated pathology in Duchenne muscular dystrophy. *Sci Transl Med* 2015, 7: 299rv4.

Bushby *et al* for the DMD Care Consideration Working Group/ *Diagnosis and management of Duchenne muscular dystrophy, part 1* Lancet Neurol. **2010** Jan;9(1):77-93 and *part 2* Lancet Neurol. **2010** Feb;9(2):177-89 .

Pinto-Mariz F, Carvalho LR, Araújo AQC, *et al*. CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy. *Skeletal Muscle* 2015, 5: 45-55.

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement was prepared for publication in Australia and may not be released or distributed in the United States. This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or to persons acting for the account or benefit of persons in the United States. Any securities described in this announcement have not been registered under the U.S. Securities Act of 1933 (the "U.S. Securities Act"), or the securities laws of any state or other jurisdiction of the United States and accordingly, may not be offered or sold to persons in the United States or to persons who are acting for the account or benefit of persons in the United States, unless they have been registered under the U.S. Securities Act, or are offered and sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.